Difference between revisions of "Carboplatin (Paraplatin)"
Jump to navigation
Jump to search
m (Text replacement - "http://chemocare.com/chemotherapy" to "https://chemocare.com/chemotherapy") |
m |
||
| Line 37: | Line 37: | ||
*[[Osteosarcoma]] | *[[Osteosarcoma]] | ||
*[[Ovarian cancer]] | *[[Ovarian cancer]] | ||
| − | |||
*[[Prostate cancer]] | *[[Prostate cancer]] | ||
*[[Small cell lung cancer]] | *[[Small cell lung cancer]] | ||
| Line 45: | Line 44: | ||
*[[Upper tract urothelial carcinoma]] | *[[Upper tract urothelial carcinoma]] | ||
</div> | </div> | ||
| + | |||
| + | ==Diseases for which it was used== | ||
| + | *[[Pancreatic cancer]] | ||
| + | |||
==Patient drug information== | ==Patient drug information== | ||
*[http://labeling.pfizer.com/ShowLabeling.aspx?id=4379 Carboplatin (Paraplatin) package insert] | *[http://labeling.pfizer.com/ShowLabeling.aspx?id=4379 Carboplatin (Paraplatin) package insert] | ||
| Line 145: | Line 148: | ||
[[Category:Osteosarcoma medications]] | [[Category:Osteosarcoma medications]] | ||
[[Category:Ovarian cancer medications]] | [[Category:Ovarian cancer medications]] | ||
| − | |||
[[Category:Prostate cancer medications]] | [[Category:Prostate cancer medications]] | ||
[[Category:Small cell lung cancer medications]] | [[Category:Small cell lung cancer medications]] | ||
| Line 152: | Line 154: | ||
[[Category:Endometrial cancer medications]] | [[Category:Endometrial cancer medications]] | ||
[[Category:Upper tract urothelial carcinoma medications]] | [[Category:Upper tract urothelial carcinoma medications]] | ||
| + | |||
| + | [[Category:Pancreatic cancer medications (historic)]] | ||
[[Category:FDA approved in 1989]] | [[Category:FDA approved in 1989]] | ||
[[Category:WHO Essential Cancer Medicine]] | [[Category:WHO Essential Cancer Medicine]] | ||
Revision as of 11:39, 26 April 2022
General information
Class/mechanism: Platinum analog, alkylating-like, producing predominantly interstrand DNA crosslinks that are cell-cycle nonspecific.[1][2]
Route: IV
Extravasation: irritant
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp,Medscape, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Dosing information
Calvert formula
- Calvert AH, Newell DR, Gumbrell LA, O'Reilly S, Burnell M, Boxall FE, Siddik ZH, Judson IR, Gore ME, Wiltshaw E. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol. 1989 Nov;7(11):1748-56. link to original article contains verified formula PubMed
Diseases for which it is used
- Adult T-cell leukemia-lymphoma
- Anaplastic glioma
- Bladder cancer
- Breast cancer
- Cervical cancer
- Diffuse large B-cell lymphoma
- Endometrial cancer
- Esophageal cancer
- Ewing sarcoma
- Extranodal NK- and T-cell lymphoma, nasal type
- Gastric cancer
- Glioblastoma
- Head and neck cancer
- Hodgkin lymphoma
- Low-grade glioma
- Mantle cell lymphoma
- Medulloblastoma
- Melanoma
- Mesothelioma
- Nasopharyngeal carcinoma
- Non-small cell lung cancer
- Osteosarcoma
- Ovarian cancer
- Prostate cancer
- Small cell lung cancer
- Testicular cancer
- Thymoma
- Unknown primary
- Upper tract urothelial carcinoma
Diseases for which it was used
Patient drug information
- Carboplatin (Paraplatin) package insert
- Carboplatin (Paraplatin) patient drug information (Chemocare)[4]
- Carboplatin (Paraplatin) patient drug information (UpToDate)[5]
History of changes in FDA indication
- 3/3/1989: Initial approval as palliative treatment of patients with ovarian carcinoma recurrent after prior chemotherapy, including patients who have previously been treated with cisplatin. (Based on SWOG 8412 and Swenerton et al. 1992)
Also known as
- Code name: JM8
- Brand names:
| Synonyms | |||||||
|---|---|---|---|---|---|---|---|
| Biocarb | Biocarbo | Bioplatinex | Biovinate | Blastocarb | Bonaplatin | Boplatex | Carbo |
| Carbokem | Carbomedac | Carbomerck | Carboplat | Carboplatine | Carboplatino | Carboplatinum | Carbosin |
| Carbotanil | Carbotec | Carbotinol | Careptin | Carplan | Carplanil | Carpsol | Crobextin |
| Cycloplatin | Cycloplatinum | Emorzim | Erbakar | Ercar | Fauldcarbo | Ifacap | Kemocarb |
| Megaplatin | Nealorin | Neocarb | Neocarbo | Oncocarb | Paraplatin | Paraplatine | Pharmaplatin |
| Platamine CS | Platinwas | Ribocarbo | Tecnocarb | Vancel | CBDCA | ||
References
Categories:
- Drugs
- Intravenous medications
- Platinum agents
- Alkylating agents
- Irritant
- Adult T-cell leukemia-lymphoma medications
- Anaplastic glioma medications
- Bladder cancer medications
- Breast cancer medications
- Carcinoma of unknown primary medications
- Cervical cancer medications
- Diffuse large B-cell lymphoma medications
- Esophageal cancer medications
- Ewing sarcoma medications
- Extranodal NK- and T-cell lymphoma, nasal type medications
- Gastric cancer medications
- Glioblastoma medications
- Head and neck cancer medications
- Hodgkin lymphoma medications
- Low-grade glioma medications
- Mantle cell lymphoma medications
- Medulloblastoma medications
- Melanoma medications
- Mesothelioma medications
- Nasopharyngeal carcinoma medications
- Non-small cell lung cancer medications
- Osteosarcoma medications
- Ovarian cancer medications
- Prostate cancer medications
- Small cell lung cancer medications
- Testicular cancer medications
- Thymoma medications
- Endometrial cancer medications
- Upper tract urothelial carcinoma medications
- Pancreatic cancer medications (historic)
- FDA approved in 1989
- WHO Essential Cancer Medicine